N. Schreiber

发表

Title : Phenotypic Heterogeneity of Circulating Tumor Cells Informs Clinical Decisions between AR Signaling Inhibitors and Taxanes in Metastatic Prostate Cancer

David S. K. Lu, H. Vargas, H. Scher, 2017 .

STEAP1 as a predictive biomarker for antibody-drug conjugate (ADC) activity in metastatic castration resistant prostate cancer (mCRPC).

M. Morris, H. Scher, J. Carrasquillo, 2015 .

Clinical Validity of Detecting Circulating Tumor Cells by AdnaTest Assay Compared With Direct Detection of Tumor mRNA in Stabilized Whole Blood, as a Biomarker Predicting Overall Survival for Metastatic Castration-Resistant Prostate Cancer Patients

H. Scher, M. Fleisher, D. Danila, 2016, Cancer journal.

Randomized Phase 2 Trial of Abiraterone Acetate Plus Prednisone, Degarelix, or the Combination in Men with Biochemically Recurrent Prostate Cancer After Radical Prostatectomy

M. Harrison, M. Morris, H. Scher, 2021, European Urology Open Science.

Safety and Efficacy of BIND-014, a Docetaxel Nanoparticle Targeting Prostate-Specific Membrane Antigen for Patients With Metastatic Castration-Resistant Prostate Cancer: A Phase 2 Clinical Trial

Michael J. Morris, Howard I. Scher, Ajjai Alva, 2018, JAMA oncology.

Nuclear-specific AR-V7 Protein Localization is Necessary to Guide Treatment Selection in Metastatic Castration-resistant Prostate Cancer.

David S. K. Lu, H. Scher, M. Fleisher, 2017, European urology.

Development of an immunofluorescent AR-V7 circulating tumor cell assay – A blood-based test for men with metastatic prostate cancer

David S. K. Lu, H. Scher, R. Krupa, 2020, Journal of circulating biomarkers.

Association of AR-V7 on Circulating Tumor Cells as a Treatment-Specific Biomarker With Outcomes and Survival in Castration-Resistant Prostate Cancer.

David S. K. Lu, H. Vargas, H. Scher, 2016, JAMA oncology.

Assessment of the Validity of Nuclear-Localized Androgen Receptor Splice Variant 7 in Circulating Tumor Cells as a Predictive Biomarker for Castration-Resistant Prostate Cancer

David S. K. Lu, H. Scher, Yipeng Wang, 2018, JAMA oncology.

Molecular characterization of circulating tumor cells (CTC) and CTC subpopulations in baseline and progressive metastatic castration resistant prostate cancer (mCRPC).

H. Scher, D. Danila, R. Krupa, 2014 .

Abstract 1588: Single cell analysis of AR N terminal, AR C terminal and the ARv7 splice variant in the CTCs of metastatic castration resistant prostate cancer (mCRPC) patients

David S. K. Lu, H. Scher, D. Rathkopf, 2015 .

Phenotypic Heterogeneity of Circulating Tumor Cells Informs Clinical Decisions between AR Signaling Inhibitors and Taxanes in Metastatic Prostate Cancer.

David S. K. Lu, H. Vargas, H. Scher, 2017, Cancer research.

The Initial Detection and Partial Characterization of Circulating Tumor Cells in Neuroendocrine Prostate Cancer

H. Beltran, J. Mosquera, H. Scher, 2015, Clinical Cancer Research.

Methicillin-Resistant Staphylococcus aureus (MRSA) Detected at Four U.S. Wastewater Treatment Plants

Xin He, A. Sapkota, A. Sapkota, 2012, Environmental health perspectives.

AR-V7 and CTC heterogeneity biomarkers additively to predict patient (pt) outcomes with taxanes relative to approved AR targeted therapy.

David S. K. Lu, H. Scher, Yipeng Wang, 2016 .

A pilot study comparing circulation tumor cells (CTC) detection by AdnaTest prostate assay to CellSearch in patients (pts) with castration resistant prostate cancer (CRPC).

H. Scher, M. Fleisher, D. Danila, 2013 .